Recent Finacing
Recent Raise
Ixaltis is a Toulouse-based biopharmaceutical research and clinical development company focused on genito-urinary diseases, developing acquired small-molecule candidates (litoxetine/IXA-001, IXA-002, IXA-003) with Phase 2 urinary incontinence trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
